Arcus Biosciences

Arcus Biosciences partners with AstraZeneca for a clinical trial to assess the safety and efficacy of combining casdatifan (HIF-2a inhibitor) and volrustomig (PD-1/CTLA-4 bispecific antibody) in clear cell renal cell carcinoma patients.

Arcus Biosciences and AstraZeneca collaborate to evaluate casdatifan (HIF-2a inhibitor) in combination with volrustomig (PD-1/CTLA-4 bispecific antibody) for clear cell renal cell carcinoma (ccRCC), marking their second clinical collaboration.

DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech and Merck. Promising drugs like Atezolizumab and ADI-270 are under various clinical trial phases, with recent FDA Fast Track designations for ADI-270 in metastatic RCC.

DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech, Allogene Therapeutics, and Merck & Co. Inc. Promising therapies such as Atezolizumab and ALLO-316 are under various clinical trial phases, with recent FDA Fast Track designations and IND approvals for novel drugs like ADI-270 and AB-2100.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.